Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया$758,943 वॉल्यूम
31 मार्च, 2026
30 जून
2%
31 दिसंबर
24%
$758,943 वॉल्यूम
30 जून
$337,208 वॉल्यूम
2%
31 दिसंबर
$156,853 वॉल्यूम
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
बाज़ार खुला: Feb 7, 2026, 5:04 PM ET
वॉल्यूम
$758,943समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
वॉल्यूम
$758,943समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent administrative actions by the Department of Justice and DEA have moved FDA-approved marijuana products and those under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act, effective April 28, 2026, following a December 2025 executive order directing expedited review. A new hearing on broader rescheduling of all marijuana begins June 29, 2026, with firm procedural deadlines to evaluate the full shift while preserving controls on illicit trafficking. These steps, building on a 2024 proposal and agency rulemaking, represent the primary drivers of trader assessments for completion timelines, with the administrative process and any resulting appeals or adjustments serving as the key variables ahead.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न